

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM316448

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Quinnova Pharmaceuticals LLC		09/04/2014	LIMITED LIABILITY COMPANY: DELAWARE
RECEIVING PARTY DATA			
Name:	Everett Laboratories, Inc.		
Street Address:	29 Spring Street West		
City:	Orange		
State/Country:	NEW JERSEY		
Postal Code:	07052		
Entity Type:	CORPORATION: NEW JERSEY		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Serial Number:	86040304	NEOCERA	
Registration Number:	4453956	PRESERA	
CORRESPONDENCE DATA			
Fax Number:	7145135130		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	714-513-5100		
Email:	mwisniewski@sheppardmullin.com		
Correspondent Name:	Michelle L. Wisniewski, Sheppard Mullin		
Address Line 1:	650 Town Center Drive		
Address Line 2:	4th Floor		
Address Line 4:	Costa Mesa, CALIFORNIA 92626		
ATTORNEY DOCKET NUMBER:	14ME-202639		
NAME OF SUBMITTER:	Michelle L. Wisniewski		
SIGNATURE:	/mlw/		
DATE SIGNED:	09/09/2014		
Total Attachments: 1			
source=Quinnova LLC Assignment#page1.tif			

CH \$65.00 86040304

TRADEMARK ASSIGNMENT

THIS TRADEMARK ASSIGNMENT is made effective as of December 12, 2013 by and between Quinnova Pharmaceuticals, LLC ("Assignor") and Everett Laboratories, Inc. ("Assignee").

RECITALS

WHEREAS, Assignor holds United States trademark Registration No. 4,453,956 for the mark **PRESERA** in connection with "dermatological pharmaceutical products; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations for use in dermatology" in Class 5 and United States trademark application Serial Number 86/040,304 for the mark **NEOCERA** in connection with "dermatological pharmaceutical products; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations for use in dermatology; topical skin formulations" in Class 5 (collectively the "Marks");

WHEREAS, Assignee is the successor to Assignor's business assets, including without limitation, the Marks along with the goodwill of Assignor's business symbolized thereby, and the portion of Assignor's business to which the Marks pertain; and

WHEREAS, Assignee desires to obtain from Assignor, and Assignor desires to assign to Assignee, all of Assignor's right, title and interest in and to the Marks, together with all of the goodwill of Assignor's business symbolized by or associated with the Marks;

ASSIGNMENT

NOW THEREFORE, for valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor assigns, transfers and conveys to Assignee all of its right, title and interest in and to the Marks, including without limitation any and all registrations, applications, and/or common law rights, together with all of the goodwill of Assignor's business symbolized by or associated with the Marks, and any and all income, royalties, damages and payments now or hereafter due and/or payable with respect thereto including, without limitation, damages and payments for past, present or future infringements.

QUINNOVA PHARMACEUTICALS, LLC

EVERETT LABORATORIES, INC.

By: James Maguire

By: Raul Kohan

Name: James Maguire

Name: Raul Kohan

Title: Chief Financial Officer

Title: Global President

Date: 9/4/2014

Date: 9/4/14